Immunogenetic Landscape of Secondary Sjögren’s Syndrome in Systemic Sclerosis and Lupus Erythematosus: Insights from Kazakhstan

Lina Zaripova 1 * , Abai Baigenzhin 2, Zhanna Zhabakova 3, Alyona Boltanova 4, Maxim Solomadin 3, Natalya Krivoruchko 5, Diana Makimova 6
More Detail
1 Department of Scientific and Innovation Management, National Scientific Medical Center, Astana, Kazakhstan
2 Chairman of the Board, National Scientific Medical Center, Astana, Kazakhstan
3 Genetic Laboratory, National Scientific Medical Center, Astana, Kazakhstan
4 Central Research Laboratory, National Scientific Medical Center, Astana, Kazakhstan
5 Rheumathology Department, Mexel Health, Astana, Kazakhstan
6 Department of Internal Medicine No.4, Astana Medical University, Astana, Kazakhstan
* Corresponding Author
J CLIN MED KAZ, Volume 22, Issue 4, pp. 6-14. https://doi.org/10.23950/jcmk/16776
OPEN ACCESS 1005 Views 209 Downloads
Download Full Text (PDF)
Author contribution. L.Z. conceptualized the study, supervised the research process, and contributed to manuscript preparation. A.B. conceived of the presented idea. L.Z. and N.K. were responsible for patient recruitment, D.M. – for clinical data collection, A.B. and Zh.Zh. for sample processing and immune analysis. M.S. and Zh.Zh. performed the genetic analyses and bioinformatic interpretation. L.Z. and L.K. drafted the manuscript, and all authors reviewed and approved the final version.

ABSTRACT

Background: Secondary Sjögren’s syndrome (sSS) frequently develops in patients systemic autoimmune diseases such as systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). Nevertheless, its immunogenetic features remain poorly understood, particularly in underrepresented populations.
Objective: To investigate the immunological and genetic characteristics of secondary Sjögren’s syndrome in Kazakh patients diagnosed with SSc and SLE.
Methods: Patients diagnosed with sSS associated with SLE and SSc were enrolled in the study. SLEDAI-2K and the modified Rodnan skin score were measured, respectively. Antinuclear factor on HEp-2 cells was analyzed by indirect immunofluorescence; autoantibody profiles were determined by immunoblotting. Interleukin (IL)-6 levels were measured by ELISA. Whole-exome sequencing was performed using a targeted panel of autoimmune-related genes. Variants were analyzed and clustered using Ion Reporter software.
Results: Antinuclear factor on Hep2 cells was positive in all SLE-sSS and 75% of SSc-sSS cases. SS-A/Ro60 and SS-A/Ro52 antibodies were frequently detected in both SLE-sSS and SSc-sSS patients, whereas SS-B antibodies were less common. Complement levels were mostly within normal ranges despite 2 SSc-sSS patients. One patient in the SSc group showed an elevated IL-6. Genetic analysis revealed likely pathogenic variants in SAMD9L, ABCC2, IL6ST, and TNFAIP3 in sSS patients.
Conclusion: This study provides insight into the immunogenetic features of secondary Sjögren’s syndrome in Kazakh patients, suggesting overlapping genetic patterns in sSS among both SSc and SLE groups. Limitations include the small sample size and cross-sectional design, which limits generalizability, but provide a foundation for further larger-scale research integrating longitudinal follow-up and comprehensive genomic profiling.
Keywords: Secondary Sjögren’s Syndrome, Systemic Sclerosis, Systemic Lupus Erythematosus, Antibodies, Genetic Predisposition.

CITATION

Zaripova L, Baigenzhin A, Zhabakova Z, Boltanova A, Solomadin M, Krivoruchko N, et al. Immunogenetic Landscape of Secondary Sjögren’s Syndrome in Systemic Sclerosis and Lupus Erythematosus: Insights from Kazakhstan. J CLIN MED KAZ. 2025;22(4):6-14. https://doi.org/10.23950/jcmk/16776

REFERENCES

  • Hussein A, Gareeballah A, Hamd ZY, Elzaki M, Abouraida RA, Eltahir MA, Khogaly M, Alsharif W, Hamad AA. Secondary Sjögren's syndrome in a rheumatoid arthritis patient: A case report and review of literature. Radiology Case Reports. 2024; 19(11): 5513-5518. https://doi.org/10.1016/j.radcr.2024.07.196
  • Negrini S, Emmi G, Greco M, Borro M, Sardanelli F, Murdaca G, Indiveri F, Puppo F. Sjögren's syndrome: a systemic autoimmune disease. Clinical and experimental medicine. 2022; 22(1): 9–25. https://doi.org/10.1007/s10238-021-00728-6
  • Zhan Q, Zhang J, Lin Y, Chen W, Fan X, Zhang D. Pathogenesis and treatment of Sjogren's syndrome: Review and update. Front Immunol. 2023; 14: 1127417. https://doi.org/10.3389/fimmu.2023.1127417
  • Both T, Dalm VA, van Hagen PM, van Daele PL. Reviewing primary Sjögren's syndrome: beyond the dryness – From pathophysiology to diagnosis and treatment. Int J Med Sci. 2017; 14(3): 191–200. https://doi.org/10.7150/ijms.17718
  • Tian Y, Yang H, Liu N, Li Y, Chen J. Advances in pathogenesis of Sjögren's syndrome. Journal of immunology research. 2021; 2021(1): 5928232. https://doi.org/10.1155/2021/5928232
  • Negrini S, Emmi G, Greco M, Borro M, Sardanelli F, Murdaca G, Indiveri F, Puppo F. Sjögren's syndrome: a systemic autoimmune disease. Clinical and experimental medicine. 2022; 22(1): 9–25. https://doi.org/10.1007/s10238-021-00728-6
  • Anaya J-M, Rojas-Villarraga A, Mantilla RD, Arcos-Burgos M, Sarmiento-Monroy JC. Polyautoimmunity in Sjögren syndrome. Rheumatic Disease Clinics. 2016; 42(3): 457–472. https://doi.org/10.1016/j.rdc.2016.03.005
  • Nezos A, Mavragani CP. Contribution of Genetic Factors to Sjögren's Syndrome and Sjögren's Syndrome Related Lymphomagenesis. J Immunol Res. 2015; 2015: 754825. https://doi.org/10.1155/2015/754825
  • Teos LY, Alevizos I. Genetics of Sjögren's syndrome. Clinical Immunology. 2017; 182: 41–47. https://doi.org/10.1016/j.clim.2017.04.018
  • Miceli-Richard C, Gestermann N, Ittah M, Comets E, Loiseau P, Puechal X, Hachulla E, Gottenberg JE, Lebon P, Becquemont L, Mariette X. The CGGGG insertion/deletion polymorphism of the IRF5 promoter is a strong risk factor for primary Sjögren's syndrome. Arthritis Rheum. 2009; 60(7): 1991–1997. https://doi.org/10.1002/art.24662
  • Teos LY, Alevizos I. Genetics of Sjögren's syndrome. Clin Immunol. 2017; 182: 41–47. https://doi.org/10.1016/j.clim.2017.04.018
  • Burbelo PD, Ambatipudi K, Alevizos I. Genome-wide association studies in Sjögren's syndrome: What do the genes tell us about disease pathogenesis? Autoimmun Rev. 2014; 13(7): 756–761. https://doi.org/10.1016/j.autrev.2014.02.002
  • Shah NR, Noll BD, Stevens CB, Brennan MT, Mougeot FB, Mougeot JC. Biosemantics guided gene expression profiling of Sjögren's syndrome: a comparative analysis with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther. 2017; 19(1): 192. https://doi.org/10.1186/s13075-017-1400-3
  • Moutsopoulos HM, Zerva LV. Anti-Ro (SSA)/La (SSB) antibodies and Sjögren's syndrome. Clin Rheumatol. 1990; 9 (1 Suppl 1): 123–130. https://doi.org/10.1007/BF02205560
  • Veenbergen S, Kozmar A, van Daele PL, Schreurs MW. Autoantibodies in Sjögren's syndrome and its classification criteria. Journal of Translational Autoimmunity. 2022; 5: 100138. https://doi.org/10.1016/j.jtauto.2021.100138
  • Veenbergen S, Kozmar A, van Daele PLA, Schreurs MWJ. Autoantibodies in Sjögren's syndrome and its classification criteria. J Transl Autoimmun. 2022; 5: 100138. https://doi.org/10.1016/j.jtauto.2021.100138
  • Zhan Q, Zhang J, Lin Y, Chen W, Fan X, Zhang D. Pathogenesis and treatment of Sjogren's syndrome: Review and update. Frontiers in immunology. 2023; 14: 1127417. https://doi.org/10.3389/fimmu.2023.1127417
  • Alani H, Henty J, Thompson N, Jury E, Ciurtin C. Systematic review and meta-analysis of the epidemiology of polyautoimmunity in Sjögren's syndrome (secondary Sjögren's syndrome) focusing on autoimmune rheumatic diseases. Scandinavian journal of rheumatology. 2018; 47(2): 141–154. https://doi.org/10.1080/03009742.2017.1324909
  • Mavragani CP, Moutsopoulos HM. Primary versus secondary Sjögren syndrome: is it time to reconsider these terms? : The Journal of Rheumatology. 2019; 46 (7): 665–666. https://doi.org/10.3899/jrheum.180392
  • André F, Böckle BC. Sjögren's syndrome. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2022; 20(7): 980–1002. https://doi.org/10.1111/ddg.14823
  • Brown LE, Frits ML, Iannaccone CK, Weinblatt ME, Shadick NA, Liao KP. Clinical characteristics of RA patients with secondary SS and association with joint damage. Rheumatology (Oxford). 2015; 54(5): 816–820. https://doi.org/10.1093/rheumatology/keu400
  • Tomizawa T, Cox T, Kollert F, Bowman SJ, Ito H, Matsuda S, Fisher BA. The impact of concomitant Sjögren's disease on rheumatoid arthritis disease activity: a systematic review and meta-analysis. Clin Exp Rheumatol. 2023; 41(12): 2484–2492. 10.55563/clinexprheumatol/oxoeuo.
  • Pasoto SG, Adriano de Oliveira Martins V, Bonfa E. Sjögren's syndrome and systemic lupus erythematosus: links and risks. Open Access Rheumatol. 2019; 11: 33–45. https://doi.org/10.2147/OARRR.S167783
  • Dammacco R. Systemic lupus erythematosus and ocular involvement: an overview. Clin Exp Med. 2018; 18(2): 135–149. https://doi.org/10.1007/s10238-017-0479-9
  • Togizbayev G, Aubakirova B, Dilmanova D, Zaripova L, Tabenova A, Karina K, Makalkina L. 2024 Comprehensive Recommendations of the Qazaq College of Rheumatology for the Diagnosis and Management of Sjögren's Syndrome. International Journal of Rheumatic Diseases. 2025; 28(5): e70272. https://doi.org/10.1111/1756-185X.70272
  • Avouac J, Sordet C, Depinay C, Ardizonne M, Vacher‐Lavenu M, Sibilia J, Kahan A, Allanore Y. Systemic sclerosis-associated Sjögren's syndrome and relationship to the limited cutaneous subtype: Results of a prospective study of sicca syndrome in 133 consecutive patients. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 2006; 54(7): 2243–2249. https://doi.org/10.1002/art.21922
  • Patel R, Shahane A. The epidemiology of Sjögren's syndrome. Clinical epidemiology. 2014; 2014(6): 247–255. https://doi.org/10.2147/CLEP.S47399
  • Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, Rasmussen A, Scofield H, Vitali C, Bowman SJ. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: a consensus and data-driven methodology involving three international patient cohorts. Annals of the rheumatic diseases. 2017; 76(1): 9–16. https://doi.org/10.1136/annrheumdis-2016-210571
  • Hernández-Molina G, Ávila-Casado C, Hernández-Hernández C, Recillas-Gispert C, Sánchez-Guerrero J. Performance of the 2016 ACR/EULAR SS classification criteria in patients with secondary Sjögren's syndrome. Clin Exp Rheumatol. 2020; 38 Suppl 126(4): 130–133.
  • Zaripova L, Baigenzhin A, Boltanova A, Iglikov T, Solomadin M, Makimova D, Kozina L, Chuvakova E. Genes, Antibodies, and Cytokines in Systemic Lupus Erythematosus: Update of Potential Biomarkers. Journal of Clinical Medicine of Kazakhstan. 2024; 21(3): 11–19. https://doi.org/10.23950/jcmk/14641
  • Sánchez-Montalvá A, Fernández-Luque A, Simeón CP, Fonollosa-Plà V, Marín A, Guillén A, Vilardell M. Anti-SSA/Ro52 autoantibodies in scleroderma: results of an observational, cross-sectional study. Clinical and experimental rheumatology. 2014; 32(6 Suppl 86): S-177-182.
  • Hamberg V, Sohrabian A, Volkmann ER, Wildt M, Löfdahl A, Wuttge DM, Hesselstrand R, Dellgren G, Westergren-Thorsson G, Rönnelid J, Andréasson K. Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis-an exploratory study. Arthritis research & therapy. 2023; 25(1): 162. https://doi.org/10.1186/s13075-023-03141-4
  • Nayebirad S, Mohamadi A, Yousefi-Koma H, Javadi M, Farahmand K, Atef-Yekta R, Tamartash Z, Jameie M, Mohammadzadegan AM, Kavosi H. Association of anti-Ro52 autoantibody with interstitial lung disease in autoimmune diseases: a systematic review and meta-analysis. BMJ open respiratory research. 2023; 10(1): 10:e002076. https://doi.org/10.1136/bmjresp-2023-002076
  • Ibrahim-Achi Z, de Vera-González A, González-Delgado A, López-Mejías R, González-Gay M, Ferraz-Amaro I. Interleukin-6 serum levels are associated with disease features and cardiovascular risk in patients with systemic sclerosis. Clinical and experimental rheumatology. 2024; 42(8): 1564–1570. https://doi.org/10.55563/clinexprheumatol/3e8ufg
  • Shahin T, Aschenbrenner D, Cagdas D, Bal SK, Conde CD, Garncarz W, Medgyesi D, Schwerd T, Karaatmaca B, Cetinkaya PG, Esenboga S, Twigg SRF, Cant C, Wilkie AOM, Tezcan I, Uhlig HH, Boztug K. Selective loss of function variants in IL6ST cause Hyper-IgE syndrome with distinct impairments of T-cell phenotype and function. Haematologica. 2019; 104(3): 609–621. https://doi.org/10.3324/haematol.2018.194233
  • Imgenberg-Kreuz J, Rasmussen A, Sivils K, Nordmark G. Genetics and epigenetics in primary Sjögren's syndrome. Rheumatology (Oxford, England). 2021; 60(5): 2085–2098. https://doi.org/10.1093/rheumatology/key330
  • Thorlacius GE, Björk A, Wahren-Herlenius M. Genetics and epigenetics of primary Sjögren syndrome: implications for future therapies. Nature reviews Rheumatology. 2023; 19(5): 288–306. https://doi.org/10.1038/s41584-023-00932-6
  • Perricone C, Bruno L, Cafaro G, Latini A, Ceccarelli F, Borgiani P, Ciccacci C, Bogdanos D, Novelli G, Gerli R, Bartoloni E. Sjogren's syndrome: Everything you always wanted to know about genetic and epigenetic factors. Autoimmunity reviews. 2024; 23(12): 103673. https://doi.org/10.1016/j.autrev.2024.103673.